Skip to main content
. 2006 Mar;168(3):1004–1021. doi: 10.2353/ajpath.2006.050471

Table 2.

Clinical Details of Patients Used in This Study

Patient no. Echo-Doppler Cholesterol Fibrinogen CRP Diabetes Leukocytes (×103)
22 Hyperecho 6.5 5.5 6.7 No 8.9
46 Hyperecho 3.9 4.5 3.1 Yes 9.7
26 Hyperecho 4.0 4.0 13.6 Yes 9.0
33 Hyperecho 4.1 3.0 2.1 No 8.0
34 Hyperecho 3.9 5.0 61.7 No 10.5
23 Hyperecho 6.5 6.5 1.7 No 4.7
4 Hyperecho 5.4 5.7 2.4 Yes 16.2
6 Hyperecho 4.7 4.1 13.9 Yes 6.1
10 Hypoecho 6.0 3.1 4.9 No 6.6
28 Hypoecho 4.3 4.4 0.9 No 6.5
20 Hypoecho 5.2 3.4 2.2 Yes 6.1
45 Hypoecho 5.3 4.8 1.5 No 9.7
7 Hyperecho 5.9 5.5 86.5 No 3.2
21 Hypoecho 3.9 5.8 0.9 Yes 6.1
42 Hypoecho 6.2 4.1 2.3 No 7.5
48 Hypoecho 4.8 3.5 34.9 No 7.3
50 Hypoecho 4.9 4.1 31.6 No 7.0
Additional plaques examined by immunohistochemistry
3 Hyperecho 4.6 3.5 0.5 No 6.3
29 Hyperecho 4.7 3.3 0.5 No 5.1
40 Hyperecho 4.5 2.2 0.9 Yes 6.3
52 Hypoecho 6.3 3.1 8.0 Yes 5.0
54 Hyperecho 5.4 6.1 0.2 No 5.3
58 Hypoecho 5.1 3.3 0.3 No 5.5
65 Hypoecho 5.3 3.4 4.3 No 9.6
78 Hypoecho 5.1 3.6 1.0 Yes 4.8
113 Hypoecho 2.8 3.2 2.5 No 5.2
121 Hypoecho 5.1 6.5 40.8 No 7.4

Bold type indicates stable plaques and italicized type indicates unstable plaques whose protein was pooled in the microarray study.